SLU-PP-332 activates ERRα/β/γ to upregulate oxidative metabolism and mitochondrial function, providing a precise tool for interrogating the ERR–PGC-1α axis in muscle, liver, and heart. Reported activities include increased oxidative muscle fibers and exercise capacity, higher whole-body energy expenditure with a shift toward lipid utilization, and protection in pressure-overload heart-failure models.
Research Significance
Pan-ERR agonism with sub-micromolar potency (ERRα EC₅₀ ~98 nM; ERRβ/ERRγ 230/430 nM).
Induces an acute aerobic-exercise transcriptional program; increases oxidative fibers and running endurance in mice.
Elevates fatty-acid oxidation and resting energy expenditure; reduces fat-mass gain in diet-induced obese and ob/ob mice without increasing food intake.
Improves ejection fraction, reduces fibrosis, and enhances survival in pressure-overload heart-failure models while normalizing cardiac metabolic profiles.
Potential Research Applications
Exercise-mimetic and endurance paradigms (fiber-type remodeling, OXPHOS capacity)
Metabolic disease models: obesity, fatty-acid oxidation, hepatic lipid handling
Mitochondrial bioenergetics assays (Seahorse/respiration, ROS, cristae integrity)
Cardiac metabolism and substrate-utilization studies under stress load
Specifications
Form: Research-grade powder (small-molecule pan-ERR agonist)
Content: SLU-PP-332
Identity: (E)-4-Hydroxy-N′-(naphthalen-2-ylmethylene)benzohydrazide; CAS: 303760-60-3; MW: 290.32; Formula: C₁₈H₁₄N₂O₂
Suggested Handling: Dissolve in research-grade DMSO (high solubility reported); prepare aliquots under sterile conditions
Storage: Store at −20 °C, protected from light and moisture
